• linkedin
  • Increase Font
  • Sharebar

    Ninjacof Recall, Tied to Previous PharmaTech Recalls

    The recall is just the latest in a bacterial contamination scare.

    Centurion Labs issued a voluntary recall of one lot of Ninjacof and Ninjacof A. The drug was distributed by Centurion and manufactured by Vilvet.

    NinjaCofSource: FDAHowever, according to the recall, Centurion was notified by the FDA that the drugs may have been manufactured in PharmaTech facility. All of PharmaTech’s liquid drug products were recently recalled due to a possible bacterial outbreak. A CDC investigation revealed bacteria present in PharmaTech drugs, prompting several cautionary recalls since. No reports have been received of adverse reactions.

    Related article: FDA Recalls All PharmaTech Liquid Drugs

    The bacterium, Burkholderia cepacia, can result in infections in patients with weakened immune systems or with chronic lung conditions.

    The affected lots are Ninjacof Lot# 200N1601 (NDC 23359-032-16) and Ninjacof A Lot# 201NA1601 (NDC 23359-033-16). Both were distributed in: Alabama, Arkansas, Florida, Georgia, Louisiana, Missouri, Mississippi, New Jersey, North Carolina, Ohio, Oklahoma, South Carolina, Tennessee, and Texas. The products are sold in 473-mL bottles with an expiration date of 11/2018.

    Ninjacof and Ninjacof are used to relieve cold and allergy symptoms.

    Questions regarding the recall can contact Centurion Customer Support: [email protected] or 601-852-3681 (M-F 8am – 5pm Central Standard Time).

    Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA’s MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available